Език: EN EN
← Назад към резултатите
Набира участници NCT07143669

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Заболявания: Clonal Mast Cell Disease KIT D816V Mutation Suspected KITD816V Mutated Clonal Mast Cell Disease

Спонсор: Blueprint Medicines Corporation

Налично на: БГ
Обобщение
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Кой може да участва
Key Inclusion Criteria: * Cohort 1 participants must meet inclusion criteria for either SMAC-A or SMAC-B: 1\. SMAC-A * Documented anaphylaxis due to Hymenoptera venom with cardiovascular symptoms or * Documented anaphylaxis without known trigger(s) or allergen(s) warranting hospitalization, emergency room visit, and/or epinephrine with cardiovascular symptoms 2. SMAC-B * Episodic or recurrent signs and symptoms consistent with mast cell activation without known triggers or allergens in at least 2 of the following organ systems: skin, respiratory/naso-ocular, gastrointestinal tract, or cardiovascular. * Any clinical response on one or more optimally dosed therapies intended to mitigate mast cell mediators, as determined by the Investigator. * Cohort 2 participants must have confirmed, known diagnosis of 1 of the following criteria: 1. Either hypermobile Ehlers-Danlos syndrome or documented history of hypermobility spectrum disorder. 2. Postural orthostatic tachycardia syndrome with one or more systemic symptoms. 3. Early onset (≤50 years old) osteoporosis or osteopenia. * Cohort 3 participants must have documented diagnosis of 1 of the following, according to World Health Organization 5th edition criteria: chronic myelomonocytic leukemia or myelodysplastic syndrome/myeloproliferative neoplasm not otherwise specified. Key Exclusion Criteria: * Participants previously diagnosed with any of the following: 1. Monoclonal mast cell activation syndrome with a known KIT mutation 2. Cutaneous mastocytosis only (that is, no documentation of systemic mast cell disease via bone marrow biopsy) 3. Any subtype of systemic mastocytosis 4. Mast cell sarcoma * Cohort 2 only: Osteopenia or osteoporosis attributed to known genetic, endocrine, nutritional, or other medical conditions. Note: Additional protocol-defined criteria apply.
Интервенции
Screening
OTHER
Места на провеждане 17
САЩ (17)
Emory University
Atlanta , Georgia
AllerVie Clinical Research
Birmingham , Alabama
O'Neal Comprehensive Cancer Center at the UAB
Birmingham , Alabama
The University of North Carolina at Chapel Hill
Chapel Hill , North Carolina
AIR Care
Dallas , Texas
AllerVie Health
Glenn Dale , Maryland
Somnos Clinical Research
Lincoln , Nebraska
Tulane University School of Medicine
New Orleans , Louisiana
Mount Sinai Hospital
New York , New York
Midwest Allergy Sinus Asthma
Normal , Illinois
Allergy, Asthma & Clinical Research Center
Oklahoma City , Oklahoma
Allergy & Clinical Immunology Associates
Pittsburgh , Pennsylvania
Kaiser Permanente San Diego
San Diego , California
Barnes-Jewish West County Hospital
St Louis , Missouri
Allergy, Asthma, & Immunology Associates of Tampa Bay
Tampa , Florida
Allergy & Asthma Clinical Research of the Bay Area
Walnut Creek , California
Care Access Research
Warwick , Rhode Island
Технически детайли
Статус
Набира участници
Вид изследване
OBSERVATIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
17.10.2025
Крайна дата
31.10.2028
Регистрационен номер
NCT07143669
Източник
clinicaltrials.gov
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.